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Abstract
Protein kinase D (PKD) is a novel family of serine/threonine kinases regulated by diacylglycerol, which is involved in multiple
cellular processes and various pathological conditions. The limited number of cell-active, selective inhibitors has historically
restricted biochemical and pharmacological studies of PKD. We now markedly expand the PKD1 inhibitory chemotype
inventory with eleven additional novel small molecule PKD1 inhibitors derived from our high throughput screening
campaigns. The in vitro IC50s for these eleven compounds ranged in potency from 0.4 to 6.1 mM with all of the evaluated
compounds being competitive with ATP. Three of the inhibitors (CID 1893668, (1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-
2-ylidene)propan-2-one; CID 2011756, 5-(3-chlorophenyl)-N-[4-(morpholin-4-ylmethyl)phenyl]furan-2-carboxamide; CID
5389142, (6Z)-6-[4-(3-aminopropylamino)-6-methyl-1H-pyrimidin-2-ylidene]cyclohexa-2,4-dien-1-one) inhibited phorbol
ester-induced endogenous PKD1 activation in LNCaP prostate cancer cells in a concentration-dependent manner. The
specificity of these compounds for PKD1 inhibitory activity was supported by kinase assay counter screens as well as by
bioinformatics searches. Moreover, computational analyses of these novel cell-active PKD1 inhibitors indicated that they
were structurally distinct from the previously described cell-active PKD1 inhibitors while computational docking of the new
cell-active compounds in a highly conserved ATP-binding cleft suggests opportunities for structural modification. In
summary, we have discovered novel PKD1 inhibitors with in vitro and cell-based inhibitory activity, thus successfully
expanding the structural diversity of small molecule inhibitors available for this important pharmacological target.
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Introduction
Protein kinase D1 (PKD1/PKCm; GenBank: ABE96833.1) is a
member of a novel family of serine/threonine kinases character-
ized by their diacylglycerol-dependent regulation. PKD1 is one of
three PKD isoforms (PKD1–3), which have well recognized roles
in cell proliferation, survival, invasion and protein transport [1].
Although functional redundancy has been documented among
PKD1–3, evidence suggests specialized roles for each isoform,
most likely due to differences in protein structure as well as
expression patterns, protein localization and substrate proximity
[2,3,4,5,6]. Extensive studies have documented a role of PKD
proteins in cancer and cardiac cell model systems; however,
considerable evidence supports roles for PKDs in neuronal
signaling pathways, DNA damage, growth factor signaling,
embryogenesis, multi-drug resistance, metabolic disorders, inflam-
mation and immune responses, further emphasizing the critical
role of PKDs across multiple biological systems [7,8,9,10,11,12].
Although loss of PKD function experiments (i.e., dominant
negative mutants, antisense oligonucleotides and RNA interfer-
ence) have been used to characterize the functional role of PKDs
in various model systems, studies had been hampered by the lack
of readily available potent and PKD specific/selective small
molecule inhibitors [13,14,15]. The lack of structural data for
PKDs hinder our ability to exploit traditional structure-based drug
design approaches to expedite the identification of more potent
and highly specific PKD inhibitors. Nevertheless, previous
comparative studies of the kinase family using sequence similarity
revealed that kinases share a conserved catalytic core where ATP
and substrate binding and phosphate transfer occurs [16].
Moreover, Thompson et al. [17] reported the three-dimensional
structure of the catalytic domain of the protein serine/threonine
kinase, cAMP-dependent protein kinase (PKA) and compared it to
a set of 10 active kinase crystal structures spanning the kinome.
Using a unique pocket clustering methodology, they found there is
little deviation with respect to the spatial conservation within
kinase active site clefts [17]. Thus, this model may be exploitable
to help characterize ATP competitive kinase inhibitors in the
absence of crystal structures.
We previously identified and characterized the first selective in
vitro PKD1 inhibitor with cellular activity: CID 755673 [18]. This
compound is a non-ATP competitive, pan-PKD inhibitor
discovered through implementation of in vitro immobilized metal
affinity for phosphochemicals (IMAP) PKD1 fluorescence polar-
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ization high throughput screening (HTS) assay [18,19]. Using CID
755673 as a parental structure, subsequent analogue development
resulted in PKD1 inhibitors with increased potency in both in vitro
and cell-based models [20,21]. Additional compounds, also
initially identified by others from in vitro HTS assays, have been
reported as PKD inhibitors, including CRT5 as well as
novel 3,5-diarylazole and 2,6-naphthyridine compounds [22,23,
24,25,26,27]. Similar to CID 755673, these compounds are pan-
PKD small molecule inhibitors with cellular inhibitory activity.
Moreover, subsequent chemical modifications of these parental
chemotypes have improved their in vitro and cellular potency and
specificity, yielding, for example, the PKD inhibitors BPKDi and
CRT0066101 [25,28]. However, direct comparison of these latter
PKD inhibitors is limited, as precise structural information is not
available for CRT0066101. Currently, it appears that all reported
PKD small molecule inhibitors have some form of liability,
including physicochemical (i.e., poor potency or specificity), off-
target effects or limited availability to the scientific community.
Herein, we describe 11 novel PKD1 inhibitory chemotypes
identified through our previous HTS campaigns. All compounds
displayed in vitro PKD1 activity in two independent in vitro assay
formats and were characterized with a series of secondary assays.
Three novel chemotypes inhibited phorbol ester-induced endog-
enous PKD1 activation (i.e., PKD Ser916 phosphorylation) in
LNCaP prostate cancer cells and were structurally dissimilar to
CID 755673, BKPDi and CRT5, revealing an expanded diversity
of PKD1 small molecule inhibitors.
Materials and Methods
Chemicals and Reagents
Black opaque small volume microtiter assay plates were
purchased from Greiner (Monroe, NC) and used for all
immobilized metal affinity for phosphochemicals (IMAPTM)-based
fluorescence polarization (FP) assay development, primary HTS
and secondary confirmation studies. IMAP progressive binding
reagent, binding buffer (,pH 5.5), kinase reaction buffer (10 mM
Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 1 mM DTT and
0.1% bovine serum albumin) and substrate peptide (FAM-
KKLNRTLSVA) were obtained from Molecular Devices (Sunny-
vale, CA). Kinase active His-tagged recombinant human protein
kinase D1 (PKD1) was obtained from Millipore (Billerica, MA).
ATP was purchased from GE Healthcare (Piscataway, NJ). H-89
and Go¨6976 were obtained from Millipore and Calbiochem,
respectively. DMSO, Syntide-2 substrate peptide and the Library
of Pharmacologically Active Compounds (LOPAC/1280 com-
pounds) set were purchased from Sigma-Aldrich (St. Louis, MO).
The 196,173 compound library screened for PKD1 small
molecule inhibitors in the IMAP FP HTS assay was made
available by the Pittsburgh Molecular Library Screening Center
(PMLSC; Pittsburgh, PA) as part of the NIH Molecular Library
Screening Center Network Roadmap Initiative (Pilot phase).
Specifically, this is diversity-based compound library obtained via
the NIH Molecular Libraries Small Molecule Repository which
collects compounds for HTS and distributed them for use by the
NIH Molecular Libraries network-designated screening Centers.
Compounds selected from the PMLSC library for further analysis
were supplied by Biofocus DPI (A Galapagos Company, San
Francisco, CA). After initial IMAP assay IC50 confirmation
studies, parental compounds were purchased from the commercial
vendors ChemDiv (PubChem CID 755673, 646236)(San Diego,
CA); Chembridge (PubChem CID 2876479, 2958734)(San Diego,
CA); InterBioScreen (PubChem CID 5389142, 663844, 2011756)
(Moscow, Russia); Nanosyn (PubChem CID 4438738 (Menlo
Park, CA); VWR (PubChem CID 16230, 9549170) (West Chester,
PA); Santa Cruz Biotechnology (PubChem CID 1893668/TG003)
(Santa Cruz, CA); and Specs-AG (PubChem CID 5086667) (Delft,
Netherlands).
IMAP-based PKD1 FP high throughput screening assay
implementation
An HTS IMAP-based PKD1 FP assay was developed and used
to screen the PMLSC library to identify primary active
compounds as previously described [18,19]. In brief, the basis
for the in vitro homogeneous IMAP PKD1 FP assay is the
interaction of nanoparticles with covalent phosphorylated moieties
generated when active PKD1 enzyme phosphorylates small,
fluorescently labeled substrate peptides. The PKD1 kinase
reactions were assembled stepwise by the addition of 36
substrate/ATP (300 nM/60 mM), compound and PKD1 enzyme
(0.18 units/mL). Positive (MAX) and negative (MIN) control
kinase reactions contained DMSO (1%) and Go¨6976 (1 mM) or H-
89 (100 mM) in 1% DMSO (final concentrations), respectively. All
assay plates were setup in a standard 384-well configuration as
previously described and all reagents were prepared in kinase
reaction buffer [19]. Kinase reactions were incubated for 90 min
at room temperature and then were stopped with the addition of
18 mL of IMAP binding reagents (1:400) in 16 binding buffer A
(proprietary composition, Molecular Devices). These nanoparticles
associate with substrate peptide phospho groups creating a larger
phosphosubstrate–nanoparticle complex. The phosphosubstrate–
nanoparticle binding can be quantified and is expressed as
millipolarization (mP) units. Inhibition of phosphosubstrate-
nanoparticle formation is reflected in lower mP signals which
suggested a potential inhibition of PKD1 enzymatic activity. Assay
plates were centrifuged at 50 g for 1 min, incubated at room
temperature for 2 hr and FP data were collected on a Molecular
Devices SpectraMax M5 (excitation A485/emission A525). This
assay was also used in secondary concentration response studies to
initially determine IC50 concentrations of compounds. IC50
determinations were performed using GraphPad Prism software
5.0 (La Jolla, CA).
Compounds were also screened for interference with the IMAP
FP assay format. Briefly, PKD1 kinase reactions were allowed to
proceed in the absence of compounds as described above.
Compounds (final concentration 10 mM) were then added to the
kinase reactions followed by the IMAP binding reagent to each
microtiter plate well. FP data were collected as described above.
Compounds exhibiting .25% inhibition of the signal were
considered to interfere with the IMAP FP assay format.
In vitro radiometric PKD assays
For compound IC50 confirmation studies, 1 ng/mL recombi-
nant human PKD1 and 20 mg Syntide-2 substrate peptide in
30 mL kinase buffer (50 mM Tris-HCl, pH 7.5, 4 mM MgCl2 and
10 mM b-mercaptoethanol) were incubated with a concentration
range (0–100 mM) of test compound. Kinase reactions were
initiated with the addition of ATP (50 mM ATP, 1.0 mCi c-33P-
ATP; Perkin Elmer, Boston, MA) and incubated for 20 min at
30uC. Twenty-five mL of the reaction was spotted onto Whatman
P81 filter paper (Whatman Inc., Clifton, NJ). Filter papers were
then washed three times in 0.5% phosphoric acid, air-dried, and
counted using an LS6500 multi-purpose scintillation counter
(Beckman Coulter, Fullerton, CA). IC50 determinations were
performed using GraphPad Prism software 5.0. Radiometric
PKD2 and PKD3 in vitro kinase assays were performed as
previously described [18].
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For ATP competition studies, recombinant human PKD1
(1 ng/mL) and Syntide-2 substrate peptide (200 ng/ml) in kinase
buffer were incubated with a concentration range of test
compound. Kinase reactions were initiated with a concentration
range of cold ATP (12.5–1000 mM) supplemented with 1.0 mCi
c-33P-ATP (Perkin Elmer) and processed as described above.
Enzyme inhibition was analyzed and visualized using the
Michaelis-Menten and Lineweaver-Burk functions of GraphPad
Prism 5.0.
Western blot analysis
Confirmed PKD1 inhibitors were also evaluated for effects on
intracellular PKD1 phosphorylation as previously described [18].
Briefly, prostate cancer cells (LNCaP) were exposed to test
compounds. Cells were lysed in buffer (200 mM Tris-HCl,
pH 7.4, 100 mM 4-(2-aminoethyl) benzenesulfonyl fluoride,
1 mM EGTA, and 1% Triton X-100) and cell lysates were
subjected to SDS-PAGE then electrotransferred to nitrocellulose
membranes. Membranes were blocked with 5% nonfat milk in
Tris-buffered saline. Membranes were probed with a primary
antibody then followed by a secondary anti-mouse or anti-rabbit
secondary antibody conjugated to horseradish peroxidase (1:1000,
Bio-Rad). Bands were visualized by the enhanced chemilumines-
cence Western blotting detection system (Amersham Biosciences).
The primary antibodies included p-S916-PKD1 antibody (Milli-
pore) and GAPDH (Enzo Life Sciences, Plymouth Meeting, PA).
HTS data analysis and visualization, statistical analysis
and database mining
Primary HTS data analysis and subsequent test compound IC50
calculations were performed using ActivityBase (IDBS, Guildford,
UK) and CytoMiner (UPDDI, Pittsburgh, PA). Additional data
visualization and statistical analysis were performed using
GraphPad Prism 5.0 and Spotfire (Somerville, MA). The
PubChem database (http://PubChem.ncbi.nim.nih.gov) was
mined to determine if the confirmed PKD1 inhibitors registered
as confirmed inhibitors in additional in vitro and cell-based assays.
MetaDrugTM, is a systems pharmacology platform specifically
designed for evaluating the biological effects of small molecule
compounds (GeneGo Inc., St. Joseph, MI). MetaDrug includes a
comprehensive chemical and pharmacological database that
comprises chemical structures of over 680,000 drugs, metabolites,
and xenobiotics along with data on their biological effects from
over 1,000,000 in vitro pharmacological-binding assays; 1,500,000
in vitro functional assays; and 600,000 in vivo functional assays.
Structural similarity, morphological similarity scoring and
molecular docking studies
Structural similarity of the confirmed inhibitors was determined
using Leadscope (Columbus, OH). Molecular alignment and
morphological similarity scoring was performed using Surflex-Sim
(Tripos, St. Louis, MO).
Flexible docking studies were performed using Molegro Virtual
Docker (MVD, University of Aarhus, Denmark) to evaluate the
potential binding of confirmed PKD1 small molecule inhibitors to
the conserved ATP binding site [29]. The basis of these docking
studies was a new hybrid search algorithm, called guided
differential evolution, which combined differential evolution
optimization with a cavity prediction algorithm that was
dynamically used during the docking process. Briefly, all individual
ligands were initialized, evaluated and scored (Escore) according to
the fitness function which was the sum of the intermolecular
interaction energy between the ligand and the protein and the
intramolecular interaction energy of the ligand (eq. 1) [29].
Escore = Einter+Eintra, with Einter being the ligand-protein inter-
action energy and Eintra being the internal energy of the ligand (eq.
1)
Einter~
X
i ligand
X
j protein
½EPLP(rij)z332:0 qiqj=4rij2
Eintra~
X
i ligand
X
j protein
EPLP(rij)z
X
flexible bonds
A½1-cos(m.H{H0)zEclash
EPLP is a piecewise linear potential using two different sets of
parameters: one set for approximating the steric van der Waals
term between atoms and the other stronger potential for hydrogen
bonds. Eclash, assigns a penalty of 1000 if the distance between two
atoms (more than two bonds apart) is less than 2.0 A˚. Thus, the
Eclash term punishes infeasible ligand conformations. Offspring was
created using a weighted difference of the parent solutions, which
were randomly selected from the population. If, and only if, the
offspring was a better fit would it replace the parent compound.
Otherwise, the parent survived and was passed on to the next
generation, representing an iteration of the algorithm. The search
process was terminated when the number of fitness evaluations
exceeded the maximum number of evaluations permitted.
Results
Identification of novel small molecule inhibitory
chemotypes for protein kinase D using a validated
automated assay system
A PKD1 IMAP FP assay was developed and optimized to
identify small molecule inhibitors of PKD1 kinase activity. Using
this assay system, we screened the LOPAC and PMLSC
compound sets (196,425 total compounds) for novel PKD
inhibitory chemotypes. The LOPAC set, a collection of 1,280
compounds of known pharmacological actions that impact many
cellular processes and includes major drug target categories, had a
dual purpose by validating our optimized automated assay system
as well as serving as a pilot screen. For the LOPAC screen each
compound was evaluated in duplicate at a single concentration
(10 mM). Eight known kinase inhibitors were identified as primary
actives ($50% inhibition of control signal) in the PKD1 IMAP FP
screen of the LOPAC set (Table S1), including previously
described nonspecific PKD1 inhibitors H7, H8 and H89 (our
assay MIN control) [30]. The validated HTS assay then was used
to screen the available full panel PMLSC diversity-based library
which consisted of 196,173 compounds. Similarly, this library was
screened at 10 mM. One hundred and nine compounds from the
PMLSC library exhibited .50% inhibition of the control signal
(for a 0.06% primary hit rate) and advanced to secondary hit
confirmation IMAP FP assays. From the LOPAC screening
activities, TG003 was prioritized to proceed to secondary
confirmation assays as the majority of the other primary active
compounds identified were known general kinase inhibitors [31].
Confirmation of PKD1 small molecule inhibitory
chemotypes by in vitro concentration response assays
False positive chemotypes were eliminated from the initially
identified putative PKD1 inhibitors by repeating the primary single
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concentration assay followed by a 10-point concentration response
assay (data not shown) [32]. Subsequently, twelve prioritized
compounds identified from the PMLSC and LOPAC screens were
obtained from commercial sources and evaluated in a radiometric
PKD1 kinase assay. All 12 chemotypes confirmed as inhibitors of in
vitro PKD1 kinase activity and ranged in potency from 0.2–6.1 mM.
Two compounds exhibited nanomolar activity (i.e., sangivamycin and
CID 755673), while the remaining ten compounds clustered with
low, single digit micromolar PKD1 inhibitory activity. Structural
cluster analysis by Leadscope indicated that all 12 chemotypes were
structurally distinct (Figure 1). Of the 12 PKD1 inhibitors, three
compounds have previously described pharmacological actions,
sangivamycin (CID 9549170), a known PKC inhibitor; amiloride
chloride (CID 16230), a sodium channel blocker; and TG-003, a
Cdc2-like kinase (Clk) inhibitor (CID 1893668) (Figure 1) [31]. None
of the 12 PKD1 inhibitory chemotypes appeared to be redox active at
concentration of #10 mM based on a previously described H2O2
generation assay (PubChem AID 878) [33].
Select novel PKD1 inhibitory chemotypes decrease the
phosphorylation of endogenous PKD1 Ser916 in LNCaP cells
Confirmed in vitro PKD1 inhibitors were then evaluated for their
ability to inhibit the phosphorylation of endogenously expressed
PKD1 Ser916, an indicator of cellular PKD1 kinase activity.
Initially, LNCaP cells were pretreated with a single concentration
(i.e., 50 mM) of test compound for 45 min, followed by PMA
stimulation at 10 nM for 20 min. Whole cell lysates were
immunoblotted for phosphorylated Ser916-PKD1 with GAPDH
serving as a loading control. As expected, CID 755673 confirmed
as a cell active PKD1 inhibitor; however, results showed that three
additional chemotypes (i.e., CID 2011756, 5389142 and 1893668)
also inhibited the phosphorylation of Ser916-PKD1 at levels
greater than 50% (Figure 2, panels A and B). Two additional
chemotypes, CID 2876479 and 5086667 displayed some cellular
inhibition of phospho-Ser916-PKD1 activity; however, the inhibi-
tion was more variable and not statistically significant. Pretreat-
ment of LNCaP cells with the remaining CIDs 16230, 2958734
and 663844 resulted in little or no inhibition of the phosphory-
lation of Ser916-PKD1 (Figure S1). Cellular EC50 values were then
determined for the three most potent, cell active PKD1 small
molecule inhibitors, CIDs 5389142, 18936668, and 2011756
(Figure 2, panel C). CIDs 5389142 and 1893668 had cellular
EC50s of 2263 (n = 3) and 52614 mM (n = 3), respectively. CID
2011756 was the most potent of the inhibitors with a cellular EC50
of 1060.7 mM (n = 3), an EC50 value comparable to that of our
previously described benzoxoloazepinolone (i.e., CID 755673).
It was also gratifying that, in general, our novel cell active PKD1
inhibitors appeared to be less promiscuous than PKD1 inhibitors
having minimal to no cellular PKD1 inhibitory activity (Table 1).
For example, CIDs 755673 and 1893668 display additional
confirmed activity in six and seven, respectively, PubChem
bioassays while CID 2011756 has confirmed activity in only one
additional PubChem bioassay. CID 5389141 has not confirmed in
any other PubChem assay. In contrast, the remaining chemotypes
registered as confirmed actives in 2–43 additional bioassays
Figure 1. Chemical structures of new PKD1 small molecule inhibitors identified through high throughput screening. New PKD1
inhibitory chemotypes were identified through HTS activities with twelve inhibitory chemotypes confirming in a radiometric PKD1 kinase assay. In
vitro IC50 values ranged from 0.2–6.1 mM. Data are represented as mean 6 range or SD of 2–4 independent experiments.
doi:10.1371/journal.pone.0025134.g001
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(Table 1). Additional chemical similarity searching, focusing on our
four novel cell-active PKD1 inhibitory chemotypes, using Meta-
Drug also supports a comparative lack of promiscuity of these
compounds. MetaDrug data mining analyses of CIDs 2011756,
5389142 and 755673 did not reveal any additional target-based
inhibitory activity of those specific parental structures (Figure S2).
However, several compounds structurally similar (70–75%) to CID
755673, showed inhibitory activity against NR2B, alpha-2C-1
adrenergic receptor, and melatonin receptors 1A and 1B (Table S2).
As expected, MetaDrug data mining for TG003 revealed its Clk1
inhibitory activity (Table S2). Moreover, we counter screened CIDs
5389142 and 2011756 in IMAP-based CDK7, AKT and PLK1
assays, and found no kinase inhibition at concentrations up to
50 mM. Taken together, these analyses suggest a low degree of
promiscuity of our novel cell active PKD1 inhibitors.
New PKD1 inhibitory chemotypes are competitive with ATP
To expedite the characterization of our PKD1 inhibitors, we
evaluated chemical structures computationally for similarities to
ATP using both Tanimoto score (TS) and morphological similarity
score (MSS) methodologies. As expected sangivamycin, a known
ATP competitive inhibitor, was predicted to be moderately to
strongly similar to ATP depending on the scoring system.
Moreover, CID 755673, a non-ATP competitive inhibitor, was
predicted to be weakly similar to ATP structure with both the TS
and MSS methodologies. Less congruency was detected between
the two predictive methodologies for the remaining 10 novel
PKD1 inhibitory compounds. However, with MSS more com-
pounds displayed a moderate similarity (MSS =,0.6) to ATP,
suggesting that our PKD1 inhibitors may be biased towards ATP
competitive scaffolds. Experimentally, these MSS predictions were
borne out with 8 of 8 tested compounds being ATP competitive
(Table 2). Figure 3 shows ATP competition data from a
representative compound, CID 5086667. Of the total nine
compounds evaluated for mechanism of action, eight compounds
were determined to be ATP competitive while the remaining
compound, CID 755673, was previously determined to be non-
ATP competitive [18]. We elected not to evaluate CID 16230,
1893668 and 663844 based on their promiscuity and/or already
existing data on mechanism of action (i.e., CID 1893668 – ATP
competitive) [31]. Moreover, preliminary in vitro data suggest that
our most potent cell active PKD1 inhibitor, CID 2011756, has
pan-PKD inhibitory effects (PKD2 IC50 = 0.660.1; PKD3
IC50 = 0.760.2 mM) with similar, albeit not identical, potencies
which may be expected for an ATP competitive inhibitor.
The cell-active PKD1 inhibitors are diverse in structure
As noted, Leadscope analysis indicated that our 12 PKD1 small
molecule inhibitors were structurally distinct with respect to each
other, highlighting the diversity of our identified chemotypes. Thus,
we next evaluated our three novel cell-active PKD1 inhibitory
compounds for structural similarity to BKPDi, CRT5 and CID
Figure 2. Select, novel PKD1 SMI display inhibition of cellular PKD1 phosphorylation at Ser916. Panels A and B, compounds were
evaluated initially for PKD1 inhibitory activity at 50 mM in LNCaP cells. Panel C, a representative Western blot shows that four compounds CID
2011756, CID 5389142, CID 1893668 and CID 755673 (control compound), displayed a concentration-dependent inhibition of PMA-induced,
endogenous PKD1 activity. Quantification of Western blotting data was determined using densitometry analysis and is graphically represented as
mean 6 SEM. Data presented are representative of three to four independent experiments. ns, not statistically significant; *, p,0.05; **p,0.01;
***, p,0.001.
doi:10.1371/journal.pone.0025134.g002
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755673 (Table 2). Data derived from both TS and MSS analyses
indicated that our new PKD1 small molecule inhibitors displayed
weak (CID 1893668) to moderate (CIDs 2011756 and 5389142)
structural similarity to the previously aforementioned cell-active
PKD1 inhibitors. Thus, it would appear we have increased the
structural diversity of cell-active PKD1 small molecule inhibitors,
encouraging the development of more potent inhibitors using these
parental structures in future structure activity relationship iterations.
Molecular docking of BKPDi, CID 2011756 and CID
5389142 to a conserved ATP binding cleft suggests CID
5389142 may afford opportunities for structural
modification to enhance its physicochemical properties
To help characterize how our novel cell-active PKD1 inhibitors are
differentiated from previously described PKD1 small molecule
inhibitors, we performed docking studies using Molegro Virtual
Docker (MVD). Predictions for interactions between the conserved
ATP binding site of PKA with the compounds described in Table 3
were evaluated [17]. We first validated our system by removing ATP
from the binding site and docked using MVD to see if the docking
pose was close to the position determined through X-ray crystallog-
raphy. All side-chain residues in the ATP-binding site were set flexible.
The dock score of 2176.75, and the low root mean square deviation
(RMSD) between the X-ray pose and best docked pose (i.e., 0.45 A˚)
suggested that the docking protocol was accurate. Figure S2 displays
the superposition between the docked pose and the X-ray pose.
BKPDi, CID 2011756 and CID 5389142 were then docked (n = 10
independent runs) into the conserved ATP binding site, poses were
generated and then ranked by energy. The lowest energy pose of the
10 poses per compound was selected for visualization (Figure 4). Data
indicated that BKPDi (Figure 4, panel A) and CID 2011756 (Figure 4,
panel C) bind tightly, although not identically, in the conserved ATP
binding cleft with a dock score of2138.68 and2136.32, respectively
(Table 3). Not surprisingly, CID 5389142, a smaller compound,
displayed a relatively low dock score of291.51 (Figure 4, panel B and
Table 3), suggesting that the smaller size of the compound may afford
more opportunities for structural enhancement.
Discussion
In the study presented here, we describe an in vitro HTS
campaign designed to identify novel inhibitory chemotypes of
PKD1 kinase activity. Using this HTS assay system, we screened
two distinct compound libraries, the LOPAC and the contempo-
rary PMLSC library, and identified and confirmed the PKD1
inhibitory activity of 12 chemotypes. CID 755673 was previously
reported by us as a potent, cell-active non-ATP competitive pan-
PKD inhibitor and has been the focus of an analogue development
strategy, which has successfully yielded multiple compounds with
increased in vitro and cellular PKD inhibitory activity. The
remaining 11 compounds identified from our screening efforts
are now described for the first time. Of these new chemotypes,
three additional compounds (i.e., CIDs 2011756, 5389142 and
1893668) exhibited cellular activity while the remaining 8
compounds displayed minimal or no cellular activity. These novel
PKD1 inhibitory chemotypes appeared to be ATP-competitive
and all are structurally unrelated. Moreover, the new cell-active
PKD1 inhibitory chemotypes were structurally distinctive from the
previously reported inhibitors BKPDi, CRT5 and CID 755673
that also have cellular activity for PKD1. Thus, we successfully
Table 1. Comparison of confirmed PKD1 small molecule inhibitors.
PubChem CID Confirmed actives/Pubchem AIDS1
Tanimoto and Morphological
Similarity Scores (T/MSS)(ATP) Mechanism of Action
Cell Active
755673 6/558 (1.1%) 0.42/0.45 Non-ATP competitive
2011756 1/444 (0.2%) 0.46/0.45 ATP competitive
5389142 0/550 (0.0%) 0.43/0.62 ATP competitive
1893668 7/632 (1.1%) 0.37/0.53 NT
Minimal
5086667 03/423 (0.7%) 0.44/0.60 ATP competitive
16230 10/710 (1.4%) 0.40/0.63 NT
646236 5/527 (1.0%) 0.32/0.60 ATP competitive
663844 43/663 (6.5%) 0.46/0.53 NT
4438738 2/404 (0.5%) 0.26/0.61 ATP competitive
2876479 20/431 (4.6%) 0.31/0.53 ATP competitive
9549170 17/430 (4.0%) 0.79/0.60 ATP competitive
2958734 7/351 (2.0%) 0.47/0.52 ATP competitive
1Pubchem checked 4/10/11. PKD1 confirmation AID not included as a confirmed active.
doi:10.1371/journal.pone.0025134.t001
Table 2. Structural dissimilarity of small molecule inhibitors
with cellular PKD1 inhibitory activity.
BKPDi CRT5 PubChem CID 755673
PubChem
CID TS2 MSS3 TS MSS TS MSS
2011756 0.55 0.60 0.47 0.57 0.57 0.40
5389142 0.47 0.57 0.44 0.59 0.46 0.15
755673 0.39 0.55 0.42 0.53 1.0 1.0
1893668 0.26 0.39 0.45 0.41 0.42 0.40
2–Tanimoto Score;
3– Morphological Similarity Score.
doi:10.1371/journal.pone.0025134.t002
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expanded the diversity of the pool of available PKD1 small
molecule inhibitors, which lay the foundation for the synthesis of
more potent, cell-active PKD1 inhibitors.
One significant advantage of our PKD1 small molecule
inhibitor studies is that all of our confirmed chemotypes described
here are available through commercial sources, allowing for an
immediate accessibility to the general scientific community. This
significant advantage is, of course, due to the types of libraries
(i.e., LOPAC and PMLSC sets) that were selected and
interrogated for PKD1 inhibitory chemotypes. A ramification of
the choice of libraries is that structural information is readily and
publicly available for compounds, allowing for multiple groups to
explore the reported biological and chemical attributes. More-
over, as our compounds are part of the PubChem database
(http://PubChem.ncbi.nlm.nih.gov/) they have been evaluated
in hundreds of in vitro and cellular screening assays, providing
insight of the potential specificity or promiscuity of a particular
chemotype. However, although data-mining PubChem (or any
other database) is an effective resource, it should be part of a
more extensive secondary screening strategy. Observations
derived from PubChem data-mining should be independently
and rigorously evaluated as the data posted is limited to an early
stage confirmation.
Potent, general kinase inhibitors, such as H-89, H-7, H-8 and
Go¨6976 have been available as PKD1 inhibitors for over 15 years
[30,34]. Due to the historic lack of PKD1 inhibitors, they became
valuable and effective research tools by necessity. However, they
are also multi-target kinase inhibitors [35,36,37]. Thus, we cannot
specifically knockdown PKD1 activity in cellular signaling
pathways using these compounds without directly impacting other
kinases. Only in the past two to three years have we seen reports
appear in the literature of potent and specific PKD1 small
molecule inhibitors [18,22,23,24,25,26,27,28]. These PKD1
inhibitors are structurally diverse and have cellular activity, but
vary in the accessibility of structural information, commercial
availability, oral bioavailability, and reported characterization.
Based on the unique aspects of CID 755673 (i.e., potency,
mechanism of action) we prioritized it for analogue development.
However, the subsequent identification of additional potent and
specific PKD1 inhibitors prompted us to revisit our other eleven
chemotypes that displayed in vitro PKD1 inhibitory activity. As a
result of our efforts, we have now identified multiple compounds
with cellular PKD1 inhibitory activity, adding to the structural
diversity of reported PKD1 small molecule inhibitors and allowing
for additional analogue development.
Historically, the paucity of PKD1 inhibitors has been a
hindrance to PKD1 studies; however, with multiple reports of
PKD1 small molecule inhibitory chemotypes, this situation
appears to be at least partially resolved. Nonetheless, the lack of
PKD1 structural information continues to be a challenge for
PKD1 research by limiting our ability to use structure-based
approaches to design more potent and specific small molecule
inhibitors. Thus, we utilized structural information of the highly
conserved kinase active site cleft to help characterize the predicted
binding profile of several ATP-competitive PKD1 small molecule
inhibitors with cellular activity. Specifically, we based our strategy
on the work of Thompson et al [27] who demonstrated that the
kinase active site cleft is highly conserved among multiple kinase
families as a single, contiguous, irregularly shaped cleft similar in
size and geometry. By docking specific PKD1 small molecule
inhibitors to this conserved active site cleft we observed that the
interaction with the kinase active site cleft may assist with the
identification of compounds for structural modification. Moreover,
this suggests that in the absence of structural data for PKD1 we
may be able to capitalize on available structural information of
Figure 3. Confirmed novel PKD1 inhibitors display competitive activity with respect to ATP. Select PKD1 inhibitors were evaluated to
determine if they were mixed, competitive or non-competitive inhibitors of ATP. Panels A and B, representative Michaelis-Menten and Lineweaver-
Burk plots of CID 5086667. This compound was found to be an ATP-competitive inhibitor. Data presented were representative of three independent
experiments.
doi:10.1371/journal.pone.0025134.g003
Table 3. Binding energies of PKD1 inhibitors with an ATP
binding domain.
PubChem CID Dock Score Mechanism of Action
ATP 2176.75 N/A
BKPDi 2138.32 ATP
5389142 291.51 ATP
2011756 2136.32 ATP
doi:10.1371/journal.pone.0025134.t003
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highly conserved protein domains or sites to assist with the design
of PKD1 small molecule inhibitors.
Supporting Information
Figure S1 Lack of potent cell-based PKD1 inhibitory
activity of CIDs 16230, 2958734 and 663844. The
remaining three in vitro active PKD1 inhibitory compounds were
screened for LNCaP cell-based activity at 50 mM. Panel A,
Representative image of a cell lysate Western blot. Panel B,
Quantification of a Western blots (mean 6 range) (n = 2). One
compound, CID 16230, exhibited less than 50% inhibitory activity
of PKD1. Due to its low activity, the cellular EC50 of CID 16230
could not be accurately determined.
(PPTX)
Figure S2 3D Structure of the cAMP-dependent protein kinase
A (PKA) (PDB ID:3fjq) and the ATP binding pocket.
(PPTX)
Table S1 Actives identified from two independent evaluations of
the LOPAC set.
(PPTX)
Table S2 MetaDrug data mining for our four novel PKD1
inhibitors with cell-based activity.
(PPTX)
Acknowledgments
The authors thank the research team at the University of Pittsburgh Drug
Discovery Institute for their technical and computer support for this
project.
Figure 4. Docking simulations of select cellular active PKD1 small molecule inhibitors in a conserved PKA catalytic core. Panel A
shows the binding pose of BPKDi (red), a cell-based PKD inhibitor, with a known mechanism of action (i.e., ATP competitive) and ATP (ball-and-stick
representation and colored by atom type). Panels B and C depict our two cellular PKD1 small molecule inhibitors and ATP docked to the conserved
catalytic domain (Panel B, CID 5389142 (blue); Panel C, CID 2011756). Panel D displays all three cellular PKD1 small molecule inhibitors (CID 5389142-
blue, CID 2011756-yellow and BPKDi-red) docked to the conserved ATP binding domain.
doi:10.1371/journal.pone.0025134.g004
Discovery of Novel and Diverse PKD1 Inhibitors
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25134
Author Contributions
Conceived and designed the experiments: ERS GMW DC SL MT QJW
RR. Performed the experiments: ERS GMW DC SL MT RR. Analyzed
the data: ERS GMW DC SL MT RR TYS QJW JSL PW. Contributed
reagents/materials/analysis tools: ERS GMW QJW JSL. Wrote the paper:
ERS GMW JSL QJW.
References
1. Wang QJ (2006) PKD at the crossroads of DAG and PKC signaling. Trends
Pharmacol Sci. pp 317–323.
2. Auer A, von Blume J, Sturany S, von Wichert G, Van Lint J, et al. (2005) Role of
the regulatory domain of protein kinase D2 in phorbol ester binding, catalytic
activity, and nucleocytoplasmic shuttling. Mol Biol Cell 16: 4375–4385.
3. Hao Q, Wang L, Tang H (2009) Vascular endothelial growth factor induces
protein kinase D-dependent production of proinflammatory cytokines in
endothelial cells. Am J Physiol Cell Physiol 296: C821–827.
4. Hao Q, Wang L, Zhao ZJ, Tang H (2009) Identification of protein kinase D2 as
a pivotal regulator of endothelial cell proliferation, migration, and angiogenesis.
J Biol Chem 284: 799–806.
5. Rey O, Yuan J, Young SH, Rozengurt E (2003) Protein kinase C nu/protein
kinase D3 nuclear localization, catalytic activation, and intracellular redistribu-
tion in response to G protein-coupled receptor agonists. J Biol Chem 278:
23773–23785.
6. Rozengurt E, Rey O, Waldron RT (2005) Protein kinase D signaling. J Biol
Chem 280: 13205–13208.
7. Avkiran M, Rowland AJ, Cuello F, Haworth RS (2008) Protein kinase d in the
cardiovascular system: emerging roles in health and disease. Circ Res 102:
157–163.
8. Besirli CG, Johnson EM, Jr. (2006) The activation loop phosphorylation of
protein kinase D is an early marker of neuronal DNA damage. J Neurochem 99:
218–225.
9. Ha CH, Wang W, Jhun BS, Wong C, Hausser A, et al. (2008) Protein kinase D-
dependent phosphorylation and nuclear export of histone deacetylase 5 mediates
vascular endothelial growth factor-induced gene expression and angiogenesis.
J Biol Chem 283: 14590–14599.
10. Matthews SA, Navarro MN, Sinclair LV, Emslie E, Feijoo-Carnero C, et al.
(2010) Unique functions for protein kinase D1 and protein kinase D2 in
mammalian cells. Biochem J 432: 153–163.
11. Oster H, Abraham D, Leitges M (2006) Expression of the protein kinase D
(PKD) family during mouse embryogenesis. Gene Expr Patterns 6: 400–408.
12. Rozengurt E (2011) Protein kinase d signaling: multiple biological functions in
health and disease. Physiology (Bethesda) 26: 23–33.
13. Azoitei N, Pusapati GV, Kleger A, Moller P, Kufer R, et al. (2010) Protein
kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in
gastrointestinal tumours. Gut 59: 1316–1330.
14. Chen J, Deng F, Singh SV, Wang QJ (2008) Protein kinase D3 (PKD3)
contributes to prostate cancer cell growth and survival through a PKCepsilon/
PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res 68: 3844–3853.
15. Kim M, Jang HR, Kim JH, Noh SM, Song KS, et al. (2008) Epigenetic
inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer
cell migration and invasion. Carcinogenesis 29: 629–637.
16. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The
protein kinase complement of the human genome. Science 298: 1912–1934.
17. Thompson EE, Kornev AP, Kannan N, Kim C, Ten Eyck LF, et al. (2009)
Comparative surface geometry of the protein kinase family. Protein Sci 18:
2016–2026.
18. Sharlow ER, Giridhar KV, LaValle CR, Chen J, Leimgruber S, et al. (2008)
Potent and selective disruption of protein kinase D functionality by a
benzoxoloazepinolone. J Biol Chem 283: 33516–33526.
19. Sharlow ER, Leimgruber S, Yellow-Duke A, Barrett R, Wang QJ, et al. (2008)
Development, validation and implementation of immobilized metal affinity for
phosphochemicals (IMAP)-based high-throughput screening assays for low-
molecular-weight compound libraries. Nat Protoc 3: 1350–1363.
20. Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, et al. (2010)
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell
growth and motility. BMC Chem Biol 10: 5.
21. Bravo-Altamirano K, George KM, Frantz MC, LaValle CR, Tandon M, et al.
(2011) Synthesis and Structure-Activity Relationships of Benzothienothiazepi-
none Inhibitors of Protein Kinase D. Acs Medicinal Chemistry Letters 2:
154–159.
22. Evans IM, Bagherzadeh A, Charles M, Raynham T, Ireson C, et al. (2010)
Characterization of the biological effects of a novel protein kinase D inhibitor in
endothelial cells. Biochem J 429: 565–572.
23. Meredith EL, Ardayfio O, Beattie K, Dobler MR, Enyedy I, et al. (2010)
Identification of orally available naphthyridine protein kinase D inhibitors. J Med
Chem 53: 5400–5421.
24. Meredith EL, Beattie K, Burgis R, Capparelli M, Chapo J, et al. (2010)
Identification of potent and selective amidobipyridyl inhibitors of protein kinase
D. J Med Chem 53: 5422–5438.
25. Monovich L, Vega RB, Meredith E, Miranda K, Rao C, et al. (2010) A novel
kinase inhibitor establishes a predominant role for protein kinase D as a cardiac
class IIa histone deacetylase kinase. FEBS Lett 584: 631–637.
26. Gamber GG, Meredith E, Zhu Q, Yan W, Rao C, et al. (2011) 3,5-Diarylazoles
as novel and selective inhibitors of protein kinase D. Bioorg Med Chem Lett 21:
1447–1451.
27. Thrower EC, Yuan J, Usmani A, Liu Y, Jones C, et al. (2011) A novel protein
kinase D inhibitor attenuates early events of experimental pancreatitis in isolated
rat acini. Am J Physiol Gastrointest Liver Physiol 300: G120–129.
28. Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, et al.
(2010) A novel small-molecule inhibitor of protein kinase D blocks pancreatic
cancer growth in vitro and in vivo. Mol Cancer Ther 9: 1136–1146.
29. Thomsen R, Christensen MH (2006) MolDock: a new technique for high-
accuracy molecular docking. J Med Chem 49: 3315–3321.
30. Johannes FJ, Prestle J, Dieterich S, Oberhagemann P, Link G, et al. (1995)
Characterization of activators and inhibitors of protein kinase C mu.
Eur J Biochem 227: 303–307.
31. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, et al. (2004)
Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol
Chem 279: 24246–24254.
32. Sharlow ER, Leimgruber S, Shun TY, Lazo JS (2007) Development and
implementation of a miniaturized high-throughput time-resolved fluorescence
energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.
Assay Drug Dev Technol 5: 723–735.
33. Soares KM, Blackmon N, Shun TY, Shinde SN, Takyi HK, et al. (2010)
Profiling the NIH Small Molecule Repository for compounds that generate
H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol 8:
152–174.
34. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, et al. (1996)
Inhibition of protein kinase C mu by various inhibitors. Differentiation from
protein kinase c isoenzymes. FEBS Lett 392: 77–80.
35. Lochner A, Moolman JA (2006) The many faces of H89: a review. Cardiovasc
Drug Rev 24: 261–274.
36. Goekjian PG, Jirousek MR (1999) Protein kinase C in the treatment of disease:
signal transduction pathways, inhibitors, and agents in development. Curr Med
Chem 6: 877–903.
37. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y (1984) Isoquinolinesulfonamides,
novel and potent inhibitors of cyclic nucleotide dependent protein kinase and
protein kinase C. Biochemistry 23: 5036–5041.
Discovery of Novel and Diverse PKD1 Inhibitors
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e25134
